Cantuzumab mertansine (SB-408075; huC242-DM1; 300 μg/kg/day for 5 days) resultes in complete regressions and cures of mice bearing human xenografts of Colo 205 colon cancer[1]. Animal Model: Female CB-17 SCID mice, 6-7 weeks of age bearing COLO 205 human colon tumor xenografts[1] Dosage: 300 μg/kg Administration: Daily for 5 days Result: Completely eliminated any measurable tumors within 2 weeks of the initiation of therapy, and all eight animals were tumor-free for 200 days (duration of the experiment).
In Vitro
Cantuzumab mertansine (SB-408075; huC242-DM1; 0-100 μM; 24 h) has selective cytotoxic activity on antigen-positive COLO 205 cell line[1]. Cell Cytotoxicity Assay[1] Cell Line: Antigen-positive COLO 205 cell line and the antigen-negative A-375 melanoma cell line Concentration: 0-100 μM Incubation Time: 24 h Result: Had cytotoxic activity on COLO 205 cells with an IC50 value of 0.032 nM (23.5 pg/ml). Had 1100-fold less cytotoxic activity for the antigen-negative A-375 cells (IC50=36 nM; 26.5 ng/ml).
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Paul R Helft, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 1;10(13):4363-8.
[2]. Anthony W. Tolcher, et al. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. J Clin Oncol. 2003 Jan 15;21(2):211-22.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
